Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

• Zacks Investment Research 3 sept

  Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?

  Ultragenyx (RARE) reported Q2 2026 earnings that beat expectations with a narrower loss of $0.90 per share versus consensus of $1.27, and revenues of $214 million surged 28.1% year-over-year, marking the company's highest quarterly revenues. However, despite the strong results, estimate revisions have trended downward over the past month, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns in the coming months.

  

• GlobeNewswire Inc. 2 sept

  Amlogenyx to Present at the Wells Fargo 21ˢᵗ Annual Healthcare Conference

  Amlogenyx, a biotechnology company developing gene therapies for Alzheimer's disease, announced it will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026. The company is developing AM805, a novel protease therapy designed to reduce amyloid accumulation in the brain, and is currently raising Series A financing for Phase 2a clinical proof of concept trials.

  

• GlobeNewswire Inc. 25 ago

  Fabry Disease Treatment Market 2026-2031 - Growth Driven by Increasing Adoption of Enzyme Replacement Therapy

  The global Fabry disease treatment market is projected to grow from USD 2.63 billion in 2025 to USD 4.09 billion by 2031, with a CAGR of 7.63%. Growth is driven by expanded screening identifying more patients, advances in gene and mRNA therapies, and sustained enzyme replacement therapy demand. However, high treatment costs remain a significant barrier to patient access, particularly in emerging markets. Asia-Pacific is expected to record the fastest growth at 8.28% CAGR.

  

• GlobeNewswire Inc. 19 jun

  Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Ultragenyx Pharmaceutical Inc. granted 44,409 restricted stock units to 15 newly hired non-executive officers on June 16, 2026, as an inducement for employment. The awards were approved by the compensation committee under the Ultragenyx Employment Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years with 25% vesting annually, contingent on continuous employment.